Aurobindo gets second OAI plant in six months
Unit-III in Pashamylaram joins Unit-I on FDA's enforcement track after an inspection with 11 observations. Warning letter or import alert possible.
— 5 earlier stories on Aurobindo Pharma Ltd. →What's new
- US FDA classified Eugia Pharma's Unit-III facility as OAI after January–February 2026 inspection.
- OAI signals serious violations and may precede warning letter or import restrictions.
- This is the second OAI for Aurobindo this year; Unit-I received similar earlier.
- Company states no immediate financial or operational impact.
Why this matters
Two OAI designations in six months suggest a pattern the US FDA is tracking. For a company with ₹84,742 cr market cap and heavy US generics exposure, even one plant under escalation restricts new approvals. The 'no immediate impact' line may hold for now, but the regulatory runway is narrowing.
What we're watching
- Whether FDA issues a warning letter or import alert for Unit-III.
- Impact on ANDA approvals from this facility.
- Remediation timeline and any reclassification.
The full read
Aurobindo Pharma's US generics business just took a second hit. The FDA classified the company's Unit-III formulation plant, operated by subsidiary Eugia Pharma, as Official Action Indicated after an 11-observation inspection in January–February 2026. That label, reserved for serious violations, puts the facility on track for a warning letter or even import restrictions. The sting: this follows a near-identical OAI at Unit-I earlier in the year. Aurobindo insists there's no immediate financial or operational impact, and at ₹84,742 cr market cap with ₹8,853 cr in quarterly sales, the company can absorb some disruption. But two OAI classifications in six months aren't a blip — they're a pattern. The open question is whether the FDA escalates enforcement, and how many pending ANDAs depend on these plants. The runway is narrowing.
Questions answered
- What does OAI mean for Aurobindo?
- Official Action Indicated means the FDA found serious violations. It can lead to a warning letter or import alert, potentially halting product shipments from that plant.
- How is this different from the Unit-I OAI earlier this year?
- This is a separate facility (Unit-III) with its own 11 observations, adding to the regulatory overhang. Combined, two OAI labels increase enforcement risk.
- Could this affect Aurobindo's revenue?
- Not immediately, per the company. However, if an import alert follows, revenue from products made at Unit-III could be blocked. The facility's exact revenue contribution is not disclosed.
- What is the company's response so far?
- Aurobindo said the classification has no immediate financial or operational impact and vowed to maintain high manufacturing standards.
- How many OAI facilities does Aurobindo now have?
- Two: Unit-I and Unit-III. Both received the classification in the past six months.
Aurobindo Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AUROPHARMA →- 12 Jun 2026 · 6:18 PM IST Aurobindo gets second OAI plant in six months
- 21d ago Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year
- 22d ago Aurobindo’s FY26 audited results are a formality. Profit growth is 0.6%.
- 22d ago Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M
- 22d ago Aurobindo's FY26 revenue grows 5.6%, profit up 2%